Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Business Segments — Allocated Share Based Compensation Expense

Similar metrics at other companies

Sarepta Therapeutics, Inc. logo
SRPTAll Other Segments — Stock-Based Comp
$29.4M-29.0%
Disc Medicine logo
IRONSignificant Segment Expense Category — Allocated Share Based Compensation Expense
$11.95M+87.7%
HCI Group logo
HCICorporate And Other — Allocated Share Based Compensation Expense
$1.94M+9.2%
AMC Entertainment Holdings logo
AMCUs Markets — Allocated Share Based Compensation Expense
$6.6M+20.0%
Vertex, Inc. logo
VERXService Other — Allocated Share Based Compensation Expense
$1.67M-1.5%
Guardian Pharmacy Services logo
GRDNCorporate — Allocated Share Based Compensation Expense
$1.86M-53.1%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's business segments — allocated share based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's business segments — allocated share based compensation expense?
Nektar Therapeutics (NKTR) reported business segments — allocated share based compensation expense of $3.36M in Q1 2026.
How has Nektar Therapeutics's business segments — allocated share based compensation expense changed year-over-year?
Nektar Therapeutics's business segments — allocated share based compensation expense decreased by 13.9% year-over-year, from $3.9M to $3.36M.
What is the long-term trend for Nektar Therapeutics's business segments — allocated share based compensation expense?
Over 2 years (2023 to 2025), Nektar Therapeutics's business segments — allocated share based compensation expense has grown at a -35.3% compound annual growth rate (CAGR), from $30.21M to $12.65M.
What does business segments — allocated share based compensation expense mean?
Reflects the portion of total share-based compensation expense attributed to the specific business segment based on employee participation. This metric captures the non-cash cost of equity-based incentives granted to personnel within this segment. It is essential for understanding the true cost of human capital and alignment of incentives within the segment's operations.